发布求助
文献互助 智能选刊 最新文献

European Oncology and Haematology最新文献

筛选
英文 中文
The Treatment of Chronic Myeloid Leukaemia (CML) in the Era of Tyrosine Kinase Inhibitors – What is New in the Battle of CML? 酪氨酸激酶抑制剂时代慢性髓性白血病(CML)的治疗- CML之战有何新进展?
European Oncology and Haematology Pub Date : 2015-01-01 DOI: 10.17925/EOH.2015.11.01.30
D. Keskin, A. E. Eşkazan
{"title":"The Treatment of Chronic Myeloid Leukaemia (CML) in the Era of Tyrosine Kinase Inhibitors – What is New in the Battle of CML?","authors":"D. Keskin, A. E. Eşkazan","doi":"10.17925/EOH.2015.11.01.30","DOIUrl":"https://doi.org/10.17925/EOH.2015.11.01.30","url":null,"abstract":"","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"77 1","pages":"30"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91220576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Mammalian target of rapamycin (mTOR) inhibition in advanced bronchial carcinoids 雷帕霉素(mTOR)抑制晚期支气管类癌的哺乳动物靶点
European Oncology and Haematology Pub Date : 2015-01-01 DOI: 10.17925/EOH.2015.11.02.100
N. Fazio, A. Frezza
{"title":"Mammalian target of rapamycin (mTOR) inhibition in advanced bronchial carcinoids","authors":"N. Fazio, A. Frezza","doi":"10.17925/EOH.2015.11.02.100","DOIUrl":"https://doi.org/10.17925/EOH.2015.11.02.100","url":null,"abstract":"","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"78 1","pages":"100-104"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83892916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autologous Transplantation in Relapsed or Refractory Hodgkin’s Lymphoma – The Challenges 自体移植治疗复发或难治性霍奇金淋巴瘤的挑战
European Oncology and Haematology Pub Date : 2015-01-01 DOI: 10.17925/EOH.2015.11.02.121
C. Gisselbrecht
{"title":"Autologous Transplantation in Relapsed or Refractory Hodgkin’s Lymphoma – The Challenges","authors":"C. Gisselbrecht","doi":"10.17925/EOH.2015.11.02.121","DOIUrl":"https://doi.org/10.17925/EOH.2015.11.02.121","url":null,"abstract":"Touch MEdical MEdia 121 Abstract Failure to initiate treatment remains a challenge in Hodgkin’s lymphoma (HL). For years, chemotherapy and stem cell transplantation salvaged less than half of relapses. Nowadays, positron emission tomography can predict the outcome under treatment. Two targeted agents are dramatically improving therapy, alone or in association with chemotherapy or stem cell transplantation. Brentuximab vedotin is an immunoconjugate anti-CD30 and anti-programmed death 1 nivolumab induces blockade of immune checkpoint. How to use them are discussed in the context of relapses/refractory HL.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"12 1","pages":"121"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79094666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lenalidomide – A Brief Review of its Use in Myelodysplastic Syndromes 来那度胺在骨髓增生异常综合征中的应用综述
European Oncology and Haematology Pub Date : 2015-01-01 DOI: 10.17925/EOH.2015.11.02.141
J. Sejpal, Yogesh R Belagali, H. Barkate
{"title":"Lenalidomide – A Brief Review of its Use in Myelodysplastic Syndromes","authors":"J. Sejpal, Yogesh R Belagali, H. Barkate","doi":"10.17925/EOH.2015.11.02.141","DOIUrl":"https://doi.org/10.17925/EOH.2015.11.02.141","url":null,"abstract":"","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"1 1","pages":"141"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90335111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antibody–Drug Conjugates in Relapsed/Refractory CD30-positive Lymphomas 复发/难治性cd30阳性淋巴瘤的抗体-药物偶联物
European Oncology and Haematology Pub Date : 2015-01-01 DOI: 10.17925/EOH.2015.11.02.123
U. Jager, M. Hutchings
{"title":"Antibody–Drug Conjugates in Relapsed/Refractory CD30-positive Lymphomas","authors":"U. Jager, M. Hutchings","doi":"10.17925/EOH.2015.11.02.123","DOIUrl":"https://doi.org/10.17925/EOH.2015.11.02.123","url":null,"abstract":"","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"10 1","pages":"123"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84101566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Long-term Survival after Cerebellar Metastasis Resection from Her2 3+ Locally Advanced Breast Cancer Her2 - 3+局部晚期乳腺癌小脑转移切除术后的长期生存率
European Oncology and Haematology Pub Date : 2015-01-01 DOI: 10.17925/EOH.2015.11.01.36
Z. Tomašević, Z. Tomašević, Z. Kovac, Z. Milovanović, D. Grujicic, R. Dzodic
{"title":"Long-term Survival after Cerebellar Metastasis Resection from Her2 3+ Locally Advanced Breast Cancer","authors":"Z. Tomašević, Z. Tomašević, Z. Kovac, Z. Milovanović, D. Grujicic, R. Dzodic","doi":"10.17925/EOH.2015.11.01.36","DOIUrl":"https://doi.org/10.17925/EOH.2015.11.01.36","url":null,"abstract":"We present a patient who first developed a distant metastatic site in the cerebellum during treatment for Her2 3+ locally advanced breast cancer (LABC). LABC was in complete remission at that time and isolated cerebellar metastasis was resected. The patient is still alive more than 135 months after LABC diagnosis, and more than 99 months after neurosurgery, and is still receiving trastuzumab without further progression or any toxicity. To the best of our knowledge, this is first report of such exceptional disease course for a patient with a predicted grave prognosis according to all prognostic parameters.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"39 1","pages":"36"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74422982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pomalidomide - An appraisal of its clinical development and role in the treatment of relapsed/refractory multiple myeloma 波马度胺-评估其临床发展和治疗复发/难治性多发性骨髓瘤的作用
European Oncology and Haematology Pub Date : 2015-01-01 DOI: 10.17925/EOH.2015.11.02.109
P. Richardson, A. Palumbo, S. Schey, M. Dimopoulos, T. Facon, K. Weisel, P. O’gorman, X. Leleu, M. Lacy, M. Streetly, J. Mikhael, D. Siegel, J. Miguel, K. Anderson
{"title":"Pomalidomide - An appraisal of its clinical development and role in the treatment of relapsed/refractory multiple myeloma","authors":"P. Richardson, A. Palumbo, S. Schey, M. Dimopoulos, T. Facon, K. Weisel, P. O’gorman, X. Leleu, M. Lacy, M. Streetly, J. Mikhael, D. Siegel, J. Miguel, K. Anderson","doi":"10.17925/EOH.2015.11.02.109","DOIUrl":"https://doi.org/10.17925/EOH.2015.11.02.109","url":null,"abstract":"","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"19 1","pages":"109-117"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76955156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Therapy for Multiple Myeloma - Quo Vadis? 多发性骨髓瘤的治疗:Quo Vadis?
European Oncology and Haematology Pub Date : 2015-01-01 DOI: 10.17925/EOH.2015.11.02.107
L. Rasche, K. M. Kortuem, H. Einsele
{"title":"Therapy for Multiple Myeloma - Quo Vadis?","authors":"L. Rasche, K. M. Kortuem, H. Einsele","doi":"10.17925/EOH.2015.11.02.107","DOIUrl":"https://doi.org/10.17925/EOH.2015.11.02.107","url":null,"abstract":"Two major developments are changing our current understanding of cancer: (1) the in-depth analysis of tumour-harbouring mutations and (2) the generation of highly active T cell-involving immunotherapies. In this editorial, we focus on its impact on myeloma therapy and speculate on future treatment concepts.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"21 1","pages":"107"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89695594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Use of Brentuximab Vedotin with or without Subsequent Allogeneic Stem Cell Transplantation in Selected Patient Groups 布伦妥昔单抗韦多汀在特定患者群体中联合或不联合异体干细胞移植的应用
European Oncology and Haematology Pub Date : 2015-01-01 DOI: 10.17925/EOH.2015.11.02.130
U. Jäger, F. Keil, M. Hutchings
{"title":"The Use of Brentuximab Vedotin with or without Subsequent Allogeneic Stem Cell Transplantation in Selected Patient Groups","authors":"U. Jäger, F. Keil, M. Hutchings","doi":"10.17925/EOH.2015.11.02.130","DOIUrl":"https://doi.org/10.17925/EOH.2015.11.02.130","url":null,"abstract":"Touch MEdical MEdia Abstract While combined chemotherapy regimens can be effective in classical Hodgkin’s lymphoma (cHL) and systemic anaplastic large cell lymphoma (sALCL), around a third of patients are unresponsive or relapse within a few years of treatment. Allogeneic stem cell transplantation (alloSCT) may achieve long-term disease control in patients with chemoresistant disease, but many patients are unable to undergo allo-SCT. Brentuximab vedotin (BV) is a novel antibody-drug conjugate targeting CD30. Recent data have suggested that this treatment may be beneficial in patients who have had an unsatisfactory response to at least two prior treatments and are not eligible for allo-SCT. In addition, BV may be used to reduce tumour burden, allowing patients to subsequently progress to allo-SCT. This article discusses case studies of treatment-refractory patients with cHL and sALCL, for whom BV has provided durable complete responses (CRs).","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"29 1","pages":"130"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84442636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hereditary Hyperferritinemia-cataract Syndrome 遗传性高铁素血症-白内障综合征
European Oncology and Haematology Pub Date : 2015-01-01 DOI: 10.17925/EOH.2015.11.02.147
C. U. Rank, J. Petersen, H. Birgens, O. Nielsen
{"title":"Hereditary Hyperferritinemia-cataract Syndrome","authors":"C. U. Rank, J. Petersen, H. Birgens, O. Nielsen","doi":"10.17925/EOH.2015.11.02.147","DOIUrl":"https://doi.org/10.17925/EOH.2015.11.02.147","url":null,"abstract":"Hereditary hyperferritinemia-cataract syndrome (HHCS) is a rare autosomal dominant disorder associated with high plasma ferritin concentration without iron overload and early-onset bilateral cataract. The deregulation of ferritin production in HHCS is caused by mutations in the iron-responsive elements (IREs) of the ferritin L-subunit gene (FTL gene) – interfering with the high-affinity interaction between IREs and iron regulatory proteins (IRPs), disturbing the negative regulatory control of ferritin synthesis and resulting in excessive production of L-ferritin. We report a 44-year-old woman initially suspected of having hereditary haemochromatosis and later together with family members diagnosed with HHCS. Genetic analysis showed heterozygosity for a G32T point mutation (Paris 2 mutation) in the IRE located in the 5′ untranslated region (UTR) of the FTL gene. The differential diagnosis of hereditary haemochromatosis and HHCS together with the rarity and the versatile phenotype in HHCS obscures the diagnostic process, which emphasises the importance of the correct diagnosis of HHCS in order to prevent unnecessary phlebotomy.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"85 1","pages":"147"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82067563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信